Leslie Meltzer insider trades
Open-market stock purchases and sales by Leslie Meltzer, Chief Research and Development at Apellis Pharmaceuticals, Inc, from SEC Form 4 filings since Aug 26, 2025.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Bought (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Bought (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $2.6M |
| Jan 28, 2026 | APLS Apellis Pharmaceuticals, Inc | Bought (not open market) | — |
Companies traded
- APLS Apellis Pharmaceuticals, Inc: other filings, last May 14, 2026